The treatment inhibited the actin-bundling into stress fibers as well as ovarian cancer cell migration by reducing GTP-bound Cdc42 and Rac1, further indicating a therapeutic role of G2 in ovarian cancer [140,150]. The gene discussed is CDC42; the disease is ovarian cancer.